循环抗CD19嵌合抗原受体T细胞（CAR-T细胞）的动力学及其亚群对弥漫性大B细胞淋巴瘤（DLBCL）患者预后的影响。 - Suppr

Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.

作者信息

Martín-Martín Lourdes, Gutiérrez-Herrero Sara, Herrero-García María, Martín García-Sancho Alejandro, Yeguas Ana, Martín-López Ana-África, López-Corral Lucía, Pérez-López Estefanía, García-Blázquez Marta, Sánchez-Guijo Fermín, Vidriales María Belén, Gaipa Giuseppe, Orfao Alberto

机构信息

Translational and Clinical Research Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Consejo Superior de Investigaciones Científicas (CSIC), and University of Salamanca, Salamanca, Spain.

Flow Cytometry Service (NUCLEUS), University of Salamanca, Salamanca, Spain.

出版信息

Blood Cancer J. 2024 May 17;14(1):83. doi: 10.1038/s41408-024-01065-z.

DOI:10.1038/s41408-024-01065-z

PMID:38760376

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11101460/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/52f1/11101460/2a60d1ea6735/41408_2024_1065_Fig1_HTML.jpg

相似文献

Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.

Blood Cancer J. 2024 May 17;14(1):83. doi: 10.1038/s41408-024-01065-z.

Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.

Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1.

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.

J Hematol Oncol. 2021 Feb 16;14(1):26. doi: 10.1186/s13045-021-01044-y.

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.

Mol Ther. 2017 Oct 4;25(10):2245-2253. doi: 10.1016/j.ymthe.2017.07.004. Epub 2017 Jul 13.

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.

A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.

Leuk Lymphoma. 2024 Jun;65(6):868-871. doi: 10.1080/10428194.2024.2325188. Epub 2024 Mar 5.

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.

Front Immunol. 2020 Nov 27;11:564099. doi: 10.3389/fimmu.2020.564099. eCollection 2020.

CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.

Clin Cancer Res. 2021 Jan 15;27(2):473-484. doi: 10.1158/1078-0432.CCR-20-1457. Epub 2020 Oct 7.

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.

Late Events After CD-19 CAR-T Treatment.

Biol Blood Marrow Transplant. 2020 Jan;26(1):e1-e2. doi: 10.1016/j.bbmt.2019.10.020. Epub 2019 Oct 25.

引用本文的文献

Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy.

Leukemia. 2025 May;39(5):1196-1205. doi: 10.1038/s41375-025-02582-x. Epub 2025 Apr 1.

[The mechanisms and salvage treatment strategies underlying positive relapse following CD19 CAR-T cell therapy in B-acute lymphoblastic leukemia].

Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):970-976. doi: 10.3760/cma.j.cn121090-20240701-00242.

Integrative single-cell multi-omics of CD19-CAR and CAR T cells suggest drivers of immunotherapy response in B cell neoplasias.

Cell Rep Med. 2024 Nov 19;5(11):101803. doi: 10.1016/j.xcrm.2024.101803. Epub 2024 Oct 28.

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is There Still a Role for Autologous Stem Cell Transplantation in the CAR T-Cell Era?

Cancers (Basel). 2024 May 23;16(11):1987. doi: 10.3390/cancers16111987.

本文引用的文献

Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.

Blood Adv. 2024 Jan 23;8(2):337-342. doi: 10.1182/bloodadvances.2023011992.

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL.

Blood Adv. 2023 Nov 28;7(22):6844-6849. doi: 10.1182/bloodadvances.2023010364.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5.

The emerging roles of γδ T cells in cancer immunotherapy.

Nat Rev Clin Oncol. 2023 Mar;20(3):178-191. doi: 10.1038/s41571-022-00722-1. Epub 2023 Jan 9.

Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma.

Clin Cancer Res. 2022 Aug 2;28(15):3378-3386. doi: 10.1158/1078-0432.CCR-22-0164.

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

Lancet Oncol. 2021 Oct;22(10):1403-1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10.

Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2021 Mar 4;384(9):842-858. doi: 10.1056/NEJMra2027612.

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.

Front Immunol. 2020 Jul 2;11:1347. doi: 10.3389/fimmu.2020.01347. eCollection 2020.

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.

Nat Med. 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0549-5. Epub 2019 Sep 2.

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献